Urology · Annapolis, MD
NPI
1629271507
Since 2007
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
600 Ridgely Ave, Suite 130
Annapolis, MD, 21401
Phone (410) 266-8049
Groups this clinician bills Medicare through
Medicare paid, 2024
$792K
19,793 services
Medicare patients, 2024
1,291
Average age 76
Drug cost, 2024
$8.5M
1,838 prescriptions
Company payments, 2025
$2,291
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jiakai Zhu was code J1952 (leuprolide injectable, camcevi, 1 mg), 4,116 times for 65 patients. In total Jiakai Zhu billed 19,793 services in 95 codes, and Medicare paid $792K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 4,116 | 65 | $45.20 | $186K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,300 | 33 | $2.27 | $5,224 |
| J0897 Injection, denosumab, 1 mg | Office | 2,100 | 22 | $20.43 | $43K |
| 87798 Infectious Agent Detection by DNA/RNA | Office | 1,421 | 107 | $34.06 | $48K |
| 81002 Clinical Chemistry | Office | 1,312 | 863 | $3.36 | $4,409 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,291 | 855 | $12.22 | $16K |
| 51798 Ultrasound - Nonspecific | Office | 1,025 | 739 | $8.79 | $9,008 |
| 99214 Office E&M - Established | Office | 947 | 610 | $91.37 | $87K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 822 | 90 | $135.04 | $111K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 567 | 204 | $50.66 | $29K |
| 99213 Office E&M - Established | Office | 449 | 379 | $64.81 | $29K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 443 | 163 | $48.41 | $21K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 289 | 110 | $39.76 | $11K |
| 96402 Chemotherapy Administration | Office | 234 | 153 | $29.20 | $6,834 |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 151 | 92 | $37.21 | $5,618 |
By year: 2022 $602K for 12,194 services; 2023 $734K for 14,820 services; 2024 $792K for 19,793 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87798 Infectious Agent Detection by DNA/RNA | 1,421 | 107 | $34.06 | $48K |
| 81002 Clinical Chemistry | 1,312 | 863 | $3.36 | $4,409 |
| 87799 Infectious Agent Detection by DNA/RNA | 113 | 107 | $40.99 | $4,631 |
| 87640 Infectious Agent Detection by DNA/RNA | 113 | 107 | $33.58 | $3,794 |
| 87641 Infectious Agent Detection by DNA/RNA | 113 | 107 | $33.58 | $3,794 |
| 87653 Infectious Agent Detection by DNA/RNA | 113 | 107 | $33.61 | $3,798 |
| 87652 Infectious Agent Detection by DNA/RNA | 112 | 106 | $39.93 | $4,472 |
| 87500 Infectious Agent Detection by DNA/RNA | 105 | 99 | $33.85 | $3,555 |
| 87481 Infectious Agent Detection by DNA/RNA | 99 | 93 | $33.81 | $3,347 |
| 87661 Infectious Agent Detection by DNA/RNA | 98 | 92 | $33.82 | $3,314 |
Medicare prescription drug claims, 2024
In 2024, the drug Jiakai Zhu prescribed most often to Medicare patients was Tamsulosin Hcl, with 337 prescriptions and refills. In total Jiakai Zhu wrote 1,838 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 337 | 904 | 126 | $6,027 |
| Orgovyx Relugolix | 295 | 295 | 47 | $775K |
| Erleada Apalutamide | 236 | 261 | 35 | $3.6M |
| Abiraterone Acetate Generic | 155 | 169 | 24 | $511K |
| Nubeqa Darolutamide | 136 | 142 | 21 | $1.8M |
| Xtandi Enzalutamide | 114 | 114 | 17 | $1.6M |
| Cefuroxime Cefuroxime Axetil | 61 | 61 | 54 | $431 |
| Prednisone Generic | 60 | 160 | 18 | $414 |
| Ciprofloxacin Hcl Generic | 53 | 53 | 50 | $111 |
| Finasteride Generic | 42 | 120 | 14 | $657 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 36 | 106 | 12 | $889 |
| Bicalutamide Generic | 28 | 45 | 13 | $544 |
| Silodosin Generic | 26 | 56 | Under 11 | $1,994 |
| Dutasteride Generic | 26 | 78 | Under 11 | $1,066 |
| Alendronate Sodium Generic | 25 | 72 | Under 11 | $249 |
Brand drugs: 840 claims; generic drugs: 998 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jiakai Zhu $2,291 ($2,291 in general payments such as food, travel and fees) from 21 companies. The largest payer was Dendreon Pharmaceuticals LLC with $316.
| Company | Payments | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 8 | $316 |
| Sumitomo Pharma America, Inc. 4506.T | 12 | $283 |
| Ferring Pharmaceuticals Inc. | 16 | $272 |
| Janssen Biotech, Inc. JNJ | 11 | $262 |
| Pfizer Inc. PFE | 12 | $251 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $118 |
| Immunitybio, Inc. IBRX | 2 | $112 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $93.46 |
| Blue Earth Diagnostics | 1 | $89.45 |
| Astellas Pharma US Inc 4503.T | 2 | $65.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.